• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Metagenomi, Inc. - Common Stock (NQ:MGX)

    2.400 -0.140 (-5.51%)
    Streaming Delayed Price Updated: 11:20 AM EST, Nov 3, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Metagenomi, Inc. - Common Stock

    Metagenomi Inc (NASDAQ:MGX) Q2 2025 Earnings: Revenue Surpasses Estimates, Loss Narrower Than Expected
    Metagenomi Inc (NASDAQ:MGX) reported Q2 2025 earnings with revenue beating estimates at $8.51M and a narrower loss of -$0.54 per share. Shares dipped slightly amid investor caution over cash burn and... 
    Via Chartmill
    Which stocks are gapping on Wednesday?
    The session on Wednesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
    Via Chartmill
    Sam Altman Says He 'Didn't Think' Elon Musk Would Abuse Government Power, Tesla CEO Hits Back With 'Scam Altman' Jibe
    OpenAI CEO Sam Altman regrets underestimating Elon Musk's potential abuse of power to block OpenAI's $500B Stargate deal. Tensions also rise with Microsoft. 
    Via Benzinga
    Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst
    Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate. 
    Via Benzinga
    Expert Outlook: Metagenomi Through The Eyes Of 4 Analysts
     
    Via Benzinga
    Peeling Back The Layers: Exploring Metagenomi Through Analyst Insights
     
    Via Benzinga
    Unveiling 4 Analyst Insights On Metagenomi
     
    Via Benzinga
    Demystifying Metagenomi: Insights From 4 Analyst Reviews
     
    Via Benzinga
    Levi Strauss To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday
     
    Via Benzinga
    Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week
    Positive data from clinical trials, earnings readouts, M&A speculation and new research drew heavy interest from retail traders on Stocktwits for these tickers for the week ended March 14, 2025. 
    Via Stocktwits
    Stargate, Netflix, GE Aerospace, Twilio, and More
    There's a lot for investors to talk about. 
    Via The Motley Fool
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
     
    Via Benzinga
    Why Netflix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
     
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
     
    Via Benzinga
    Cogent Communications To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Monday
     
    Via Benzinga
    MGX Stock Earnings: Metagenomi Beats EPS, Beats Revenue for Q2 2024
    MGX stock results show that Metagenomi beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
    Via InvestorPlace
    MGX Stock Earnings: Metagenomi Misses EPS, Beats Revenue for Q1 2024
    MGX stock results show that Metagenomi missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
    Via InvestorPlace
    Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025 Formula, Stock Soars
    Moderna reports Q1 loss, beating sales estimates amidst declining COVID-19 vaccine demand. Cost-saving measures drive optimism for investors. CEO Stéphane Bancel eyes strategic investments. Guidance... 
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
     
    Via Benzinga
    3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire
    Pay close attention to gene editing stocks. By 2028, according to MarketsandMarkets, the market could be worth about $10.6 billion. 
    Via InvestorPlace
    12 Health Care Stocks Moving In Friday's After-Market Session
     
    Via Benzinga
    This Biotech IPO Stock Just Took a Tumble, But Don't Give Up on It Yet
    A bumpy start can't detract from this company's strong balance sheet. 
    Via The Motley Fool
    Topics Initial Public Offering
    Gilead-Backed Kyverna Overshoots Raised IPO Expectations
    Kyverna Therapeutics raised almost $320 million in its initial public offering, which was priced above the marketed range. Backed by Gilead Sciences, the company's offering was the second largest for a... 
    Via Talk Markets
    Topics Initial Public Offering
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.